MDxHealth SA operates as a molecular diagnostics company in Belgium, the Netherlands, Spain, Poland, Italy, the United States, rest of European Union, and internationally. The company develops and commercializes epigenetic and other molecular tests for cancer assessment and the personalized treatment of patients. Its tests are based on proprietary genetic, epigenetic, and other molecular technologies, as well as assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The company's product pipeline includes tests for bladder, kidney, and other urologic cancers. Its products include ConfirmMDx, a tissue test for prostate cancer; and SelectMDx, a non-invasive urine test for prostate cancer. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
The current price of MDXH.BOATS is $2.37 USD — it has decreased by -22.04% in the past 24 hours. Watch MDxHealth SA stock price performance more closely on the chart.
What is MDxHealth SA stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange MDxHealth SA stocks are traded under the ticker MDXH.BOATS.
When is the next MDxHealth SA earnings date?▼
MDxHealth SA is going to release the next earnings report on May 14, 2026.
What were MDxHealth SA earnings last quarter?▼
MDXH.BOATS earnings for the last quarter are -0.17 USD per share, whereas the estimation was -0.13 USD resulting in a -35.48% surprise. The estimated earnings for the next quarter are N/A USD per share.
How many employees does MDxHealth SA have?▼
As of April 04, 2026, the company has 177 employees.